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Background: To measure changes in duplex velocity estimates associ-
ated with balloon expandable (BES) and self-expandable (SES) endoluminal
stents.
Methods: An in vitro vascular circuit model consisting of a pulsatile
pump, tubing, and a conduit was created. The pump was programmed to
replicate the doppler spectral waveform pattern of the renal and carotid
arteries. Conduits consisted of Sylgard® (Dow Corning, Midland, MI)
tubing of variable compliance with differing wall thicknesses. An intralumi-
nal fluid was created using a cornstarch and water mixture which had an
average viscosity of 3.46 cP over the range of fluid velocities observed in this
study. Pressure was measured continuously by electromechanical transducer
at a site proximal to the conduit. Flow velocities were estimated with duplex
ultrasound utilizing a matrix linear array probe at 6-15 MHZ (GE Logic
E-9, GE Healthcare). Peak systolic velocity (PSV) and end-diastolic velocity
(EDV) were estimated at 5 distinct conduit locations. Three replicate
velocity measurements were made at each location. Diameter measurements
of the conduit at peak systole and end diastole were made, and change in
cross-sectional area calculated. After initial velocity estimates, a BES or SES
was deployed within the conduit. Velocity estimates were then repeated.
Three separate conduits were used. Analysis of PSV and EDV measured
under the three arterial conditions (unstented, BES, and SES) was per-
formed using mixed linear models that included a random effect to account
for clustering. Fixed effects were included for condition, location (five
segments marked on each conduit and denoted “A” - “E”), and replicate (1,
2, or 3). All analyses were performed using SAS version 9.2 software.
Results: Compliance was estimated for each conduit under each condi-
tion (unstented, BES, and SES). Values ranged from 3.12  103 to 8.43 
103mm2/mmHg. Average PSVs differed by condition.Mean SE PSVwas
95.8 2.6 cm/s, 97.0 2.7 cm/s, and101.4 2.7 cm/s for unstented, BES
and SES, respectively (P  .0001). Average PSVs differed significantly across
location (P .0001) and replicate (P .039); however, no interaction between
condition and either location or replicate were found. EDV values did not differ
significantly across condition. Mean  SE EDV was 36.2 1.0 cm/s,
37.3 1.1 cm/s, and 37.2 1.1 cm/s for unstented, BES and SES, respec-
tively (P .13). Average EDVs differed significantly across location (P .001)
but not across replicates (P .82). The direct effect of stenting on velocities was
assessed by examining paired differences between the unstented and stented
conduits calculated at each replicate. Mean  SE percent change in PSV was
1.0 3.3% for BES minus unstented, and 6.4 3.1% for SES minus un-
stented (P .24). Mean SE change in EDV was 1.3 5.3% for BES minus
unstented, and 3.5 4.4% for SES minus unstented (P  .79). Overall esti-
mates of the effect of stent placement (pooled across BES and SES types) were
3.7% (95% CI: 6.4%, 13.8%) for PSV, and 0.8% (95% CI: 7.1%, 8.3%) for
EDV.
Conclusions: The presence of BES and SES were associated with a less
than 7% change in estimated PSV. These results suggest that Doppler
velocity estimates for renal and carotid arteries are not materially affected by
either ballon expandable or self expandable endoluminal stents.
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Background: Postmenopausal women taking hormone replacement
therapy (HRT) have increased intimal hyperplasia (IH) following vascular
intervention. Matrix metalloproteinases (MMPs) play a major role in IH
development, and we have shown that hormone exposure results in unbal-
anced MMP regulation in vascular smooth muscle cells in vitro. Previously
we presented data from a small pilot study suggesting a role for HRT in the
development of IH via MMP modulation in vivo, using a postmenopausal
rodent model of vascular injury. Here we further investigated the role of
HRT as a modulator of MMPs and IH in a larger follow-up study.
Methods: Female rats were aged to 12 months and ovariectomized
(OVX). Four weeks later estrogen (E), progesterone (P), estrogen  pro-
gesterone (E/P), or placebo (Plac) were delivered via 90-day slow-release
pellets. Following 6 weeks of HRT, each rat underwent balloon angioplasty
of the left common carotid artery. At 14 days postinjury, tissue samples were
collected and stained with Trichrome elastin for intima:media (I:M) mea-
surement and stained for various MMP isoforms.
Results: Following vascular injury I:M was decreased in OVX rats
compared to non-OVX controls (Fig 1, n 5-6, PNS). In OVX animals,
HRT exposure did not significantly increase the I:M ratios. (Fig 1, n 5-6,
P  NS). Injury-induced expression of MMP-2 and 9 was significantlydecreased in OVX animals compared to non-OVX controls (Table 1; n 
5-6). MMP-2 and 9 levels were subsequently increased by each type of
hormone therapy compared to placebo, with a significant increase in
MMP-9 in response to estrogen with and without progesterone (Table; n
5-6). Conversely, TIMP-2 was significantly decreased by estrogen compared




NonOVX C OVX - Plac OVX - E OVX - P OVX - EP
MMP-2 37.8  10.0 15.4  3.7* 26.5  3.7 38.8  7.6 38.5  7.6
MMP-9 4.3  0.1 2.7  0.4* 4.7  0.6# 6.0  1.3 7.1  1.0#
TIMP-2 50.9  8.9 22.2  3.4* 8.7  1.4# 24.8  10.1 28.2  9.4
*P  0.05 vs. NonOVX C
#P  0.05 vs. OVX-Plac
Conclusions: Here we were not able to demonstrate a statistically
significant decrease in IH as a result of ovariectomy. Furthermore, HRT at
the doses given did not remarkably increase IH. Here we also demonstrate a
significant reduction in MMP-2, 9, and TIMP-2 in response to ovariec-
tomy. Subsequent hormone exposure results in the upregulation of MMP-2
and9 without a counter-regulatory increase in TIMP. We have previously
shown elevation in MT1-MMP to occur during the initial phases of IH
development; therefore, examination earlier than 14 days postinjury is
needed to determine the effect of HRT on this MMP regulatory isoform.
Future studies should investigate in vivo manipulation of this unbalanced
MMP regulation for prevention of IH in response to HRT exposure.
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Background: Endovascular abdominal aortic aneurysm repair (EVAR)
of intact abdominal aortic aneurysm (AAA) continues to gain favor despite
the perceived higher procedural costs when compared to open repair
(OPEN). National trends in AAA repair are unknown. This study aims to
compare regional utilization of EVAR, and its effects on patient mortality
and procedural costs.
Methods: All patients in the Medicare database who underwent AAA
repair from 2004 to 2007 were identified and stratified into OPEN and
EVAR cohorts. Geographic regions were created according to standard US
census divisions. Primary outcomes included perioperative mortality, long-
term survival and hospital cost.
Results: There were 103,033 patients identified, 68,370 EVAR
(66.4% ) vs 34,6633 OPEN (33.6%). Although EVAR is favored nationally,
there are significant differences in regional utilization (Table). Between
2004 and 2007, the total number of AAA repairs was not different (25,246
vs 25,850, P  NS), but the percentage of EVARS performed was signifi-
cantly higher in 2007 (14,001 [55%] vs 19,471 [75%], P  .001). The
national 30-daymortality was significantly higher after OPEN (4.9% vs 1.6%,
P  .001), however, long-term survival was equal(73.6% OPEN vs 74.6%
EVAR P  .04) with no regional differences (Table). Hospital charges for
EVARwere significantly less than open ($64,380 EVAR vs $68,174 OPEN,
P  .0001), as was Medicare reimbursement ($19,367 EVAR vs $23,474
OPEN, P  .001). This is likely due to an increased length-of-stay in the
OPEN cohort (3.5 days EVAR vs 9.9 days OPEN, P  .001)
